Gansu Longshenrongfa Pharmaceutical Industry300534.SZValuation Analysis

As of Oct 19, 2026, Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ) trades at a P/E of 95.00x, P/B of 4.58x, P/S of 4.93x, and a dividend yield of 0.37%.
Longitudinal percentile comparison: P/E sits at the 29th percentile over the trailing 10Y window (vs. 60th percentile over 3Y); P/B sits at the 72nd percentile over the trailing 10Y window (vs. 73rd percentile over 3Y); P/S sits at the 33rd percentile over the trailing 10Y window (vs. 89th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 80th percentile within its industry and the 79th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.37%, ranking at the 86th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 42.8 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Gansu Longshenrongfa Pharmaceutical Industry operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.